Safety and Survival Outcomes of<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior<sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Oliver Sartor, Ralph A. Bundschuh et al.|Journal of Nuclear Medicine|2022Cited by 37